인슐린 전달 기기 시장 : 유형별, 질환 유형별 - 예측(-2030년)

Insulin Delivery Device Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (Tethered, Tubeless), Insulin Pen Needle (Standard, Safety), Insulin Syringes, Others), Disease Type (Type 1 Diabetes, Type 2 Diabetes) - Global Forecast to 2030

US $ 4,950 ￦ 6,877,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,238,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,322,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,893,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 인슐린 전달 기기 시장 규모는 2025년 353억 달러에서 2030년까지 527억 달러에 이를 것으로 예상되며, 예측 기간에 CAGR로 8.3%를 나타낼 것으로 전망됩니다.

시장은 여러 요인에 의해 일관된 성장을 보여주고 있으며, 세계적인 고령화에 따라 당뇨병과 같은 질병의 유병률이 상승하여 진보된 인슐린 전달 기기 수요 증가로 이어지고 있습니다.

조사 범위
조사 대상 연도	2024-2030년
기준 연도	2024년
예측 기간	2024-2030년
단위	10억 달러
부문	유형, 질병 유형, 최종 사용자, 지역
대상 지역	북미, 유럽, 아시아태평양, 중동, 아프리카, 라틴아메리카

AI와 머신러닝(ML)의 통합 등 인슐린 전달 기기의 기술적 진보도 이 수요에 기여하고 있습니다.

전반적으로 당뇨병 치료에 중점을 둔 의료비 증가는 당뇨병 유병률 증가로 시장 확대에 새로운 기회를 키우고 있습니다.

인슐린 펜 유형별로 재사용 가능한 인슐린 펜 부문은 2024년 시장에서 가장 큰 점유율을 차지했습니다.

재사용 가능한 인슐린 펜은 프리필드 인슐린 카트리지를 보유하도록 설계된 딜리버리 챔버를 갖추고 있습니다.

엑세터 대학이 2024년에 실시한 최근 조사에 따르면 영국에서는 연간 약 400만개의 일회용 인슐린 펜이 처방되었으며, 그 결과 약 79톤의 플라스틱 폐기물이 발생하여 1,000톤의 이산화탄소를 배출했습니다. 이에 비해 재사용 가능한 인슐린 펜은 이 폐기물을 크게 줄일 수 있어 보다 지속 가능한 선택이 됩니다.

2024년, 재택 케어 환경 부문이 시장에서 가장 큰 점유율을 차지했습니다.

이 동향은 주로 환자들 사이에서 인슐린의 자가 투여에 대한 선호가 높아지고 있기 때문입니다.

첨단의 사용하기 쉬운 전달 기기의 상시나, 제조업체의 환자 훈련의 제공에 주력, 주요 시장에서 인슐린 자기 투여에 대한 상환을 받는 것 등, 여러 요인이 이 동향을 지지해 왔습니다. 첨단 기술을 이용한 펌프와 펜니들도 도입되어 왔으며, 이러한 신제품은 침습성이 낮은 기술을 사용하여 정확한 양의 인슐린을 투여할 수 있도록 설계되어 있습니다.

2024년 북미는 시장에서 가장 큰 점유율을 차지했습니다.

이것은 주로 이 지역에서 1형 당뇨병의 유병률 향상으로 인한 것입니다.

이 보고서는 세계의 인슐린 전달 기기 시장에 대한 조사 분석을 통해 주요 성장 촉진요인 및 억제요인, 경쟁 구도, 미래 동향 등의 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 조사 결과

• 인슐린 전달 기기 : 시장 개요
• 북미의 인슐린 전달 기기 시장 : 유형별, 국가별
• 인슐린 전달 기기 시장 : 지리적 구성
• 인슐린 전달 기기 시장 : 지역의 구성
• 인슐린 전달 기기 시장 : 선진국 시장 vs. 개발도상국 시장

제5장 시장 개요

• 서론
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 규제 분석
  • 규제기관, 정부기관, 기타 조직
  • 규제 틀
• 산업 동향
  • 하이브리드 폐루프 시스템/인공 췌장 디바이스 시스템 수요 증가
  • 스마트 인슐린 펜과 연속 혈당 모니터링 시스템의 동기화에 의해 당뇨병 데이터의 공유가 촉진
  • 이해 관계자간의 제휴 증가
• 상환 시나리오
• 기술 분석
• 주요 회의 및 이벤트
• 가격 분석
  • 인슐린 전달 기기의 참고 가격 동향 : 주요 기업별
  • 인슐린 전달 기기의 참고 가격 동향 : 지역별
• 무역 분석
• 특허 분석
  • 인슐린 전달 기기의 특허 공보 동향
  • 관할 분석 : 인슐린 전달 기기 시장에서 상위 특허 출원자
• 공급망 분석
• 밸류체인 분석
• 에코시스템 시장 맵
• 사례 연구 분석
• Porter's Five Forces 분석
• 주요 이해관계자와 구매 기준
• 인접 시장 분석
• 투자 및 자금조달 시나리오
• 인슐린 전달 기기 시장에서의 미충족 요구/최종 사용자의 기대
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 인슐린 전달 기기 시장에 대한 AI/생성형 AI의 영향

제6장 인슐린 전달 기기 시장 : 유형별

• 서론
• 인슐린 펜
• 인슐린 펌프
• 인슐린 펜니들
• 인슐린 주사기
• 기타 인슐린 전달 기기

제7장 인슐린 전달 기기 시장 : 질환별

• 서론
• 1형 당뇨병
• 2형 당뇨병

제8장 인슐린 전달 기기 시장 : 최종 사용자별

• 서론
• 재택 케어 환경
• 병원 및 진료소
• 기타 최종 사용자

제9장 인슐린 전달 기기 시장 : 지역별

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시 경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 아시아태평양의 거시 경제 전망
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 라틴아메리카의 거시 경제 전망
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 중동 및 아프리카의 거시 경제 전망
  • GCC 국가
  • 중동의 중동 및 아프리카

제10장 경쟁 구도

• 서론
• 주요 진입기업의 전략/강점
• 수익 분석(2022-2024년)
• 시장 점유율 분석(2024년)
• 기업 평가 매트릭스 : 주요 기업(2024년)
• 기업의 평가 매트릭스 : 스타트업/중소기업(2024년)
• 브랜드/제품 비교
• 기업 평가 및 재무 지표
• 주요 기업의 R&D 평가
• 경쟁 시나리오

제11장 기업 프로파일

• 주요 기업
  • EMBECTA CORP.(FORMERLY BECTON, DICKINSON AND COMPANY DIABETES CARE BUSINESS)
  • NOVO NORDISK A/S
  • MEDTRONIC
  • SANOFI
  • ELI LILLY AND COMPANY
  • TANDEM DIABETES CARE, INC.
  • INSULET CORPORATION
  • BIOCON
  • ROCHE DIABETES CARE
  • HTL-STREFA(SUBSIDIARY OF THE MTD GROUP)
  • YPSOMED
  • MEDTRUM TECHNOLOGIES INC.
  • TERUMO CORPORATION
  • WOCKHARDT LIMITED
  • NIPRO
• 기타 기업
  • CEQUR CORPORATION
  • EOFLOW CO. LTD.
  • HINDUSTAN SYRINGES & MEDICAL DEVICES LTD
  • SOOIL DEVELOPMENTS CO. LTD
  • SUNGSHIM MEDICAL CO. LTD.
  • B.BRAUN SE
  • DEBIOTECH SA
  • JIANGSU DELFU MEDICAL DEVICE CO. LTD
  • HASELMEIER(A SUBSIDIARY OF MEDMIX)
  • MANNKIND CORPORATION

제12장 부록

KTH

영문 목차

영문목차

The global insulin delivery devices market is projected to reach USD 52.7 billion by 2030 from USD 35.3 billion in 2025, at a CAGR of 8.3% during the forecast period. The insulin delivery devices market is experiencing consistent growth due to several factors. As the global population ages, the prevalence of conditions like diabetes is rising, leading to an increased demand for advanced insulin delivery devices. Additionally, government support and favorable reimbursement schemes are further promoting market growth.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2024-2030
Units Considered	Value (USD billion)
Segments	Type, Disease Type, End User, and Region
Regions covered	North America, Europe, Asia Pacific, Middle East & Africa, and Latin America

Technological advancements in insulin delivery devices, such as the integration of artificial intelligence (AI) and machine learning (ML), have also contributed to this demand. Furthermore, an increase in research and development activities, along with strategic partnerships, is creating additional opportunities for growth in the market.

Overall, the rise in healthcare expenditure focused on diabetes care, combined with the increasing prevalence of diabetes, is fostering new opportunities for market expansion.

The reusable insulin pens segment accounted for the largest share of the insulin delivery devices market, by type of insulin pen, in 2024.

The insulin delivery devices market can be categorized into several types: insulin pens, insulin pumps, insulin syringes, insulin pen needles, and other insulin delivery devices. Within the category of insulin pens, there are two main types: reusable insulin pens and disposable insulin pens. As of 2024, reusable insulin pens held the largest market share.

Reusable insulin pens feature a delivery chamber designed to hold prefilled insulin cartridges. These devices are more cost-effective than disposable insulin pens, leading to their increasing popularity for insulin delivery. They provide significant advantages in terms of affordability, sustainability, and user-friendliness. Additionally, reusable pens offer environmental benefits.

A recent study from the University of Exeter in 2024 reported that approximately four million single-use insulin pens are prescribed annually in England, resulting in about 79 tons of plastic waste and emitting 1,000 tons of carbon dioxide, which is equivalent to the emissions from 250 additional cars on the road. In contrast, reusable insulin pens can significantly reduce this waste, making them a more sustainable option. Consequently, a growing number of end users are opting for reusable insulin pens, driving the segment's growth.

In 2024, the home care settings segment held the largest share of the insulin delivery devices market.

The insulin delivery devices market is categorized by end users into home care settings, hospitals & clinics, and other end users. In 2024, the home care settings segment held the largest market share. This trend is primarily attributed to the increasing preference for self-administration of insulin among patients. One of the main advantages of self-administration is the time and cost savings it offers, as patients can avoid the need for regular visits to healthcare providers for insulin administration. Additionally, self-administration can enhance medication adherence and improve treatment outcomes.

Several factors support this trend, including the launch of advanced, user-friendly delivery devices, manufacturers' focus on providing patient training, and the availability of reimbursements for insulin self-administration in key markets. Over the years, the market has also seen the introduction of technologically advanced pumps and pen needles designed to help patients manage diabetes through self-administration. These new products are designed to deliver precise amounts of insulin using minimally invasive techniques. Collectively, these factors are driving growth in this segment of the market.

In 2024, North America accounted for the largest share of the insulin delivery devices market.

The global market for insulin delivery devices is divided into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest share of this market, primarily due to the rising prevalence of type 1 diabetes in the region. Since type 1 diabetes is dependent on insulin, the increasing number of diabetes patients is driving up demand for insulin delivery devices.

According to the International Diabetes Federation (IDF) Atlas 2025, approximately 1.4 million individuals in the US and 240,000 in Canada were reported to be living with type 1 diabetes in 2024. This growing patient population is fueling a continuous demand for various insulin delivery devices, including pens, pumps, syringes, and pen needles.

Additionally, the North American region is witnessing significant investments in research and development aimed at enhancing insulin delivery technologies. Companies in the area are actively working to improve patient convenience, accuracy, and connectivity of these devices to meet the evolving needs of healthcare professionals and patients. The combination of high disease prevalence, technological advancements, and a robust healthcare infrastructure ensures that North America remains a leading region in the global insulin delivery devices market.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (50%), Director-level Executives (30%), and Others (20%)
• By Region: North America (30%), Europe (25%), Asia Pacific (20%), Latin America (15%), and the Middle East & Africa (10%)

Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.

Note 2: C-level executives include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The players operating in the insulin delivery devices market include Embecta Corp.(US), Novo Nordisk A/S (Denmark), Ypsomed (Switzerland), Medtronic (Ireland), Tandem Diabetes Care, Inc. (US), Sanofi (France), and Eli Lilly and Company (US), Tandem Diabetes Care, Inc. (US), Insulet Corporation (US), Biocon (India), Roche Diabetes Care (Switzerland), HTL-STREFA, a subsidiary of the MTD Group (Poland), Ypsomed (Switzerland), Medtrum Technologies Inc. (China), Terumo Corporation (Japan), Wockhardt Limited (India), Nipro (Japan), Cequr Corporation (Switzerland), Eoflow Co., Ltd. (South Korea), Hindustan Syringes & Medical Devices Ltd. (India), SOOIL Developments Co., Ltd. (South Korea), SUNGSHIM MEDICAL CO., LTD (South Korea), B. Braun SE (Germany), Debiotech SA (Switzerland), Jiangsu Delfu Medical Device Co., Ltd. (China), Haselmeier, a Medmix company (Germany), and Mankind Corporation (US).

Research Coverage

This report studies the insulin delivery devices market based on type, disease type, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will allow both established companies and smaller or new firms to assess market trends, helping them increase their market share. Companies that purchase the report can employ one or more of the strategies outlined below to enhance their market presence.

This report provides insights on the following pointers:

• Analysis of key drivers (growing prevalence of diabetes, technological advancements in insulin delivery devices, government support, and favorable reimbursement schemes), restraints (high cost and lack of reimbursement in developing countries, needle anxiety in patients, and alternative drug delivery methods), opportunities (increasing research and development activities and strategic partnerships, increasing healthcare expenditure on diabetes care, advances in syringe and needle technology, and mandates pertaining to safety-engineered medical needles), challenges (needlestick injuries and misuse of injection pens and lack of interoperability among insulin delivery devices)
• Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the insulin delivery devices market
• Product Development/Innovation: Comprehensive understanding of the forthcoming trends, research and development initiatives, and product launches within the insulin delivery devices market
• Market Development: Complete knowledge about profitable developing regions
• Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the insulin delivery devices industry helps to diversify the market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed (Switzerland), Medtronic (Ireland), Tandem Diabetes Care, Inc. (US), Sanofi (France), and Eli Lilly and Company (US)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 STUDY INCLUSIONS AND EXCLUSIONS
  • 1.3.2 MARKETS COVERED
  • 1.3.3 YEARS CONSIDERED FOR STUDY
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 ASSUMPTIONS FOR STUDY
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 SCOPE-RELATED LIMITATIONS
  • 2.6.2 METHODOLOGY-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 INSULIN DELIVERY DEVICES: MARKET OVERVIEW
• 4.2 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET, BY TYPE AND COUNTRY
• 4.3 INSULIN DELIVERY DEVICES MARKET: GEOGRAPHICAL MIX
• 4.4 INSULIN DELIVERY DEVICES MARKET: REGIONAL MIX
• 4.5 INSULIN DELIVERY DEVICES MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growth in prevalence of diabetic population
    • 5.2.1.2 Technological advancements in insulin delivery devices
    • 5.2.1.3 Government support and favorable reimbursement schemes to favor the market growth
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost and lack of reimbursement in emerging economies
    • 5.2.2.2 Needle anxiety in patients to affect growth of pen needles and syringes market
    • 5.2.2.3 Oral insulin as alternative drug delivery method
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increase in research & development activities and strategic partnerships
    • 5.2.3.2 Increase in healthcare expenditure on diabetes care
    • 5.2.3.3 Advances in insulin syringe and needle technology
    • 5.2.3.4 Mandates pertaining to safety-engineered medical needles
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Needlestick injuries and misuse of injection pens
    • 5.2.4.2 Lack of interoperability among insulin delivery devices
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.3.2 REGULATORY FRAMEWORK
    • 5.3.2.1 North America
      • 5.3.2.1.1 US
      • 5.3.2.1.2 Canada
    • 5.3.2.2 Europe
    • 5.3.2.3 Asia Pacific
      • 5.3.2.3.1 Japan
      • 5.3.2.3.2 China
      • 5.3.2.3.3 India
      • 5.3.2.3.4 Australia
    • 5.3.2.4 Latin America
      • 5.3.2.4.1 Brazil
      • 5.3.2.4.2 Mexico
    • 5.3.2.5 Middle East
    • 5.3.2.6 Africa
• 5.4 INDUSTRY TRENDS
  • 5.4.1 GROWING DEMAND FOR HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS
  • 5.4.2 SYNCHRONIZATION OF SMART INSULIN PENS WITH CONTINUOUS GLUCOSE MONITORING SYSTEMS PROMOTES DIABETES DATA SHARING
  • 5.4.3 INCREASE IN NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS
• 5.5 REIMBURSEMENT SCENARIO
  • 5.5.1 GLOBAL COVERAGE AND REIMBURSEMENT
• 5.6 TECHNOLOGY ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Automated insulin delivery
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Bluetooth
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Continuous glucose monitoring
• 5.8 KEY CONFERENCES & EVENTS
• 5.9 PRICING ANALYSIS
  • 5.9.1 INDICATIVE PRICING TREND OF INSULIN DELIVERY DEVICE, BY KEY PLAYER
  • 5.9.2 INDICATIVE PRICING TREND OF INSULIN DELIVERY DEVICE, BY REGION
• 5.10 TRADE ANALYSIS
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS FOR INSULIN DELIVERY DEVICES
  • 5.11.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN INSULIN DELIVERY DEVICES MARKET
• 5.12 SUPPLY CHAIN ANALYSIS
• 5.13 VALUE CHAIN ANALYSIS
• 5.14 ECOSYSTEM MARKET MAP
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 OMNIPOD 5 FACILITATED EFFECTIVE INSULIN MANAGEMENT FOR YOUNG ATHLETES, SUPPORTING CONTINUITY IN TRAINING AND COMPETITION
  • 5.15.2 MEDTRONIC MINIMED INSULIN PUMP ENHANCED GLUCOSE CONTROL, IMPROVING DAILY MANAGEMENT FOR PEOPLE WITH DIABETES
  • 5.15.3 SMART INSULIN DELIVERY WITH MEDTRONIC INPEN FOR IMPROVED DIABETES MANAGEMENT
• 5.16 PORTER'S FIVE FORCES ANALYSIS
  • 5.16.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.16.2 BARGAINING POWER OF SUPPLIERS
  • 5.16.3 BARGAINING POWER OF BUYERS
  • 5.16.4 THREAT OF SUBSTITUTES
  • 5.16.5 THREAT OF NEW ENTRANTS
• 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.17.2 BUYING CRITERIA
• 5.18 ADJACENT MARKET ANALYSIS
• 5.19 INVESTMENT & FUNDING SCENARIO
• 5.20 UNMET NEEDS/END-USER EXPECTATIONS IN INSULIN DELIVERY DEVICES MARKET
• 5.21 TRENDS/DISRUPTION IMPACTING CUSTOMER'S BUSINESS
• 5.22 IMPACT OF AI/GENERATIVE AI ON INSULIN DELIVERY DEVICES MARKET

6 INSULIN DELIVERY DEVICES MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 INSULIN PENS
  • 6.2.1 ADVANCED AND CONVENIENT SOLUTIONS FOR INSULIN ADMINISTRATION TO DRIVE MARKET
  • 6.2.2 REUSABLE INSULIN PENS
    • 6.2.2.1 Technology innovations offering cost-effectiveness to boost growth
  • 6.2.3 DISPOSABLE INSULIN PENS
    • 6.2.3.1 Ease of use to drive market, though shift toward eco-friendly environment can challenge growth
• 6.3 INSULIN PUMPS
  • 6.3.1 PRECISION OFFERED BY NEWER AND MORE REFINED TECHNOLOGY TO DRIVE INSULIN PUMPS MARKET
  • 6.3.2 TETHERED INSULIN PUMPS
    • 6.3.2.1 Increase in collaborations and partnerships between companies to develop integrated CGM systems to drive market
  • 6.3.3 TUBELESS INSULIN PUMPS
    • 6.3.3.1 Use of artificial intelligence and technological advancements to boost market
• 6.4 INSULIN PEN NEEDLES
  • 6.4.1 STANDARD INSULIN PEN NEEDLES
    • 6.4.1.1 Affordability of standard insulin pen needles over safety pen needles to propel growth
  • 6.4.2 SAFETY INSULIN PEN NEEDLES
    • 6.4.2.1 Reduced chances of infection and accidental pricking to drive market
• 6.5 INSULIN SYRINGES
  • 6.5.1 COMMONLY USED DELIVERY MEANS CHALLENGED BY SAFETY CONCERNS AND AWARENESS OF AFFORDABLE ALTERNATIVES
• 6.6 OTHER INSULIN DELIVERY DEVICES

7 INSULIN DELIVERY DEVICES MARKET, BY DISEASE TYPE

• 7.1 INTRODUCTION
• 7.2 TYPE 1 DIABETES
  • 7.2.1 CHRONIC NATURE OF TYPE 1 DIABETES, COMBINED WITH SIGNIFICANT INCIDENCE IN CHILDREN AND YOUNG ADULTS, TO DRIVE GROWTH
• 7.3 TYPE 2 DIABETES
  • 7.3.1 RISING PREVALENCE OF TYPE 2 DIABETES, DRIVEN BY LIFESTYLE-RELATED RISK FACTORS AND EARLIER DISEASE ONSET TO FUEL MARKET

8 INSULIN DELIVERY DEVICES MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOME CARE SETTINGS
  • 8.2.1 INCREASE IN AFFORDABILITY OF SELF-MONITORING SYSTEMS AND INSULIN DELIVERY DEVICES TO FUEL SELF/HOME HEALTHCARE
• 8.3 HOSPITALS & CLINICS
  • 8.3.1 RISE IN DEMAND FOR POINT-OF-CARE TESTING IN HOSPITALS TO BOOST MARKET GROWTH
• 8.4 OTHER END USERS

9 INSULIN DELIVERY DEVICES MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 Largest share of North American insulin delivery device market
  • 9.2.3 CANADA
    • 9.2.3.1 Rise in government support to boost market in Canada
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Germany to dominate European insulin delivery devices market
  • 9.3.3 UK
    • 9.3.3.1 Government support and research funding to drive market growth in UK
  • 9.3.4 FRANCE
    • 9.3.4.1 High insurance coverage and increasing affordability to fuel market
  • 9.3.5 ITALY
    • 9.3.5.1 Increase in government spending to drive insulin delivery device growth in Italy
  • 9.3.6 SPAIN
    • 9.3.6.1 Minimal co-payments and full reimbursement to drive market growth in Spain
  • 9.3.7 REST OF EUROPE (ROE)
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 China to dominate Asia Pacific's insulin delivery devices market
  • 9.4.3 JAPAN
    • 9.4.3.1 Rise in aging population and high diabetes cases to drive growth in Japan
  • 9.4.4 INDIA
    • 9.4.4.1 Rise in diabetes cases and affordable local manufacturing to fuel insulin device demand in India
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Government subsidies to support market growth
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Rise in diabetes cases and strong government healthcare support to boost market
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Brazil to account for largest share in Latin American insulin delivery devices market
  • 9.5.3 MEXICO
    • 9.5.3.1 Growth in regulatory support to propel market
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR THE MIDDLE EAST & AFRICA
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Rise in diabetes prevalence and high per capita healthcare expenditure to drive market in GCC countries
  • 9.6.3 REST OF THE MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INSULIN DELIVERY DEVICES MARKET
• 10.3 REVENUE ANALYSIS, 2022-2024
• 10.4 MARKET SHARE ANALYSIS, 2024
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Type footprint
    • 10.5.5.3 Region footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING
    • 10.6.5.1 DETAILED LIST OF KEY STARTUPS/SMES, 2024
    • 10.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
• 10.7 BRAND/PRODUCT COMPARISON
• 10.8 COMPANY VALUATION & FINANCIAL METRICS
  • 10.8.1 FINANCIAL METRICS
  • 10.8.2 COMPANY VALUATION
• 10.9 R&D ASSESSMENT OF KEY PLAYERS
• 10.10 COMPETITIVE SCENARIO
  • 10.10.1 PRODUCT LAUNCHES & APPROVALS
  • 10.10.2 DEALS
  • 10.10.3 EXPANSIONS
  • 10.10.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 EMBECTA CORP. (FORMERLY BECTON, DICKINSON AND COMPANY DIABETES CARE BUSINESS)
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product launches and approvals
      • 11.1.1.3.2 Deals
      • 11.1.1.3.3 Expansions
      • 11.1.1.3.4 Other developments
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 NOVO NORDISK A/S
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches and approvals
      • 11.1.2.3.2 Deals
      • 11.1.2.3.3 Other developments
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 MEDTRONIC
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches and approvals
      • 11.1.3.3.2 Deals
      • 11.1.3.3.3 Expansions
      • 11.1.3.3.4 Other developments
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 SANOFI
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product launches and approvals
      • 11.1.4.3.2 Expansions
      • 11.1.4.3.3 Other developments
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Right to win
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 ELI LILLY AND COMPANY
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches and approvals
      • 11.1.5.3.2 Deals
      • 11.1.5.3.3 Expansions
      • 11.1.5.3.4 Other developments
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Right to win
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses and competitive threats
  • 11.1.6 TANDEM DIABETES CARE, INC.
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product launches and approvals
      • 11.1.6.3.2 Deals
  • 11.1.7 INSULET CORPORATION
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches and approvals
      • 11.1.7.3.2 Deals
      • 11.1.7.3.3 Expansions
      • 11.1.7.3.4 Other developments
  • 11.1.8 BIOCON
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Deals
      • 11.1.8.3.2 Other developments
  • 11.1.9 ROCHE DIABETES CARE
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product launches and approvals
  • 11.1.10 HTL-STREFA (SUBSIDIARY OF THE MTD GROUP)
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Deals
  • 11.1.11 YPSOMED
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Product launches and approvals
      • 11.1.11.3.2 Deals
      • 11.1.11.3.3 Expansions
      • 11.1.11.3.4 Other developments
  • 11.1.12 MEDTRUM TECHNOLOGIES INC.
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
  • 11.1.13 TERUMO CORPORATION
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product launches and approvals
      • 11.1.13.3.2 Deals
      • 11.1.13.3.3 Expansions
      • 11.1.13.3.4 Other developments
  • 11.1.14 WOCKHARDT LIMITED
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Product launches and approvals
      • 11.1.14.3.2 Other developments
  • 11.1.15 NIPRO
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Expansions
• 11.2 OTHER PLAYERS
  • 11.2.1 CEQUR CORPORATION
  • 11.2.2 EOFLOW CO., LTD.
  • 11.2.3 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD
  • 11.2.4 SOOIL DEVELOPMENTS CO., LTD
  • 11.2.5 SUNGSHIM MEDICAL CO., LTD.
  • 11.2.6 B.BRAUN SE
  • 11.2.7 DEBIOTECH SA
  • 11.2.8 JIANGSU DELFU MEDICAL DEVICE CO., LTD
  • 11.2.9 HASELMEIER (A SUBSIDIARY OF MEDMIX)
  • 11.2.10 MANNKIND CORPORATION

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS

관련자료